Skip to main content

Nivolumab

Question for Department of Health

UIN 10597, tabled on 17 September 2015

To ask the Secretary of State for Health, what estimate he has made of the number of lung cancer patients who would benefit from the immunotherapy nivolumab; and if he will make a statement.

Answered on

14 October 2015

NHS England has advised that it is not currently possible to estimate the numbers of patients in England who will be suitable for treatment, as the licence for nivolumab has been split into two distinct sub-groups (squamous and non-squamous non-small cell lung cancer) and the latter has yet to receive a marketing authorisation.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.